66 filings
8-K
IBRX
ImmunityBio, Inc.
17 Jul 24
Entry into a Material Definitive Agreement
9:48pm
8-K
IBRX
ImmunityBio, Inc.
12 Jun 24
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
IBRX
ImmunityBio, Inc.
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
8-K
IBRX
ImmunityBio, Inc.
23 Feb 24
Departure of Directors or Certain Officers
9:28pm
8-K
IBRX
ImmunityBio, Inc.
2 Jan 24
ImmunityBio Announces $320 Million Investment by Oberland
6:08am
8-K
edemg clt5fp89x
11 Sep 23
ImmunityBio Announces $470 Million Equity and Debt Financing
6:25am
8-K
157r4lfhboc0r97
1 Sep 23
Other Events
8:30am
8-K
j2vq25m0p2 n8
15 Aug 23
Other Events
4:15pm
8-K
qy7tm ps40xzn1
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
nqt fxlllw
20 Jul 23
Other Events
4:07pm
8-K
ltlgfe2
14 Jun 23
Entry into a Material Definitive Agreement
5:15pm
8-K
4whk3 cdm
11 May 23
Other Events
6:45am
8-K
uq2r4zys g8k5p
31 Mar 23
Entry into a Material Definitive Agreement
4:29pm
8-K
dlns5gaa
20 Mar 23
Other Events
8:31am
8-K
4tcadsnlmq1t3zu nt
15 Feb 23
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
9:20am
8-K
z7bxb944
14 Feb 23
Results of Operations and Financial Condition
5:25pm
8-K
i88055nccxa viz
13 Feb 23
Other Events
8:02am
8-K
uln mq7acg1qky87ioj7
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
5wwg gzeprqze34rm4
5 Dec 22
Other Events
10:51am
8-K
iqobnvixo m4f92
15 Nov 22
Regulation FD Disclosure
8:42am